Sepúlveda Mucientes, Cristian y Moraga Calvo, Jorge. 2013. La rítmica corporal: 16 Repertorio y Propuesta Metodológica. Seminario de título, Profesor Especializado en Teoría General de la Música

Este seminario de titulo corresponde a un trabajo de creación, enmarcado en el área de la educación musical especializada, el cual tiene por finalidad proveer de material musical como apoyo a la labor docente específica de la rítmica corporal. Este trabajo surge desde la práctica y representa la integración de los conocimientos adquiridos en el transcurso de la carrera de Licenciatura en Artes con mención en Teoría de la Música (Facultad de Artes, Universidad de Chile)

Intrathecal cell therapy with autologous stromal cells increases cerebral glucose metabolism and can offer a new approach to the treatment of Alzheimer's type dementia

After recent observations that intrathecal administration of autologous bone marrow mesenchymal stromal cells (MSCs) increases cerebral metabolism in patients with severe traumatic brain injury (TBI), we examined this type of cell therapy in Alzheimer's type dementia. Three patients with clinical diagnosis of Alzheimer's disease received every 3 months 100million autologous MSCs by intrathecal route, until a total dose of 300million. During cell therapy the patients showed arrest in neurological deterioration and two of them manifested clear improvement of previous symptoms. A global increase in cerebral glucose metabolism, measured using 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), was observed after every administration of cell therapy. Our present findings suggest that intrathecal administrations of autologous MSCs can be a new strategy for the treatment of Alzheimer's dementiaWe thank the institutions supporting the development of our cell therapy program, in particular Mapfre and Rafael del Pino Foundation

Impact of intrathecal cell therapy with autologous stromal cells on short-term memory binding in early Alzheimer's disease : one-year follow-up assessment of two cases

Background: We had previously reported that the administration of autologous stromal cells (ASCs) therapy to two patients with mild AD dementia led to a global increase in cerebral glucose metabolism which was accompanied by significant improvement of visual short-term memory binding (VSTMB), a function known to be a marker of AD. We suggested that intrathecal administration of autologous ASCs could be considered a new therapeutic strategy for AD dementia (Vaquero et al., 2019). We were interested in investigating the post-intervention durability of such cognitive improvements. Methods: We studied two AD patients with cerebral beta-amyloid neuritic plaques detected with 18FFDG-PET. The patients received every three months 100 million of ASCs by intrathecal route, until a total dose of 300 million. None received any other medication for its disease at the time of receiving cell therapy. Clinical and neuroimaging studies were performed previous and after the therapy, including brain glucose metabolism by 18F-FDG-PET and assessment with the visual short-term memory binding task (VSTMBT). This task has been proposed as a preclinical marker of AD. It requires subjects to detect whether or not two combinations of shape and colour change across two sequential arrays. Here we report on the assessment of these patients one year after the therapy. We compared them with 4 AD patients who did no undergo stem cell therapy. Results: Single case statistics revealed that benefits drawn by treated patients from the therapy remained a year after. Using a more taxing version of the VSTMB test (memory load of 3 items) we observed that, after the therapy, the chance that an untreated AD patient would show more impairment was 75.45% (p= 0.24) for Case 1 and 89.23% (p=0.11) for case 2. This chance remained after 1 year post-treatment for Case 1 (75.45%, p=0.24) and increased for Case 2 (96.89%, p=0.031). Conclusion: Improvements of memory functions known to be marker for AD in patients who underwent stem cell therapy remained stable after one year post-intervention. This offers a new therapeutic strategy for AD

Adding value to tumor staging in head and neck cancer: The role of metabolic parameters as prognostic factors

Background: Validated biomarkers in head and neck squamous cell carcinoma (HNSCC) are scarce. Methods: We retrospectively analyzed 62 patients with HNSCC treated with radiotherapy +/− concurrent chemotherapy. Pretreatment metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were measured in a 18F-FDG positron emission tomography using a liver dependent standardized uptake value threshold. Cox regression analyses were performed to find associations with disease-free survival (DFS) and overall survival (OS). Results: High values of MTV (>37 ml) were independently associated with a worse DFS (hazard ratio [HR] = 3.45; 95% confidence interval [CI], 1.52–7.84) and OS (HR = 3.27; 95% CI, 1.41–7.57). Similar results were found for high values of TLG (>247 g) for DFS (HR = 3.32; 95% CI, 1.44–7.65) and OS (HR = 3.42; 95% CI, 1.45–8.07). Conclusions: MTV and TLG can be considered as independent prognostic factors for DFS and OS in patients with HNSCC. Considering how easily obtainable they are, they may be useful for predicting clinical outcomes in these patient

Preliminary evidence of the impact of intrathecal cell therapy with autologous stromal cells on short-term memory binding in early Alzheimer’s disease cases

Background: A decrease in brain glucose metabolism in Alzheimer’s disease (AD) patients is considered a critical driver of cognitive impairment, and medications used in AD target this metabolic dysfunction. Recent evidence has shown a significant increase in glucose metabolism associated with neurocognitive improvement after intrathecal administration of bone marrow mesenchymal stromal cells (MSCs) in patients suffering from severe TBI or haemorrhagic stroke. We hypothesise that this cell therapy could also be useful in AD patients. Methods: We studied two AD patients with cerebral beta-amyloid neuritic plaques detected with 18FFDG-PET. The patients received every three months 100 million of autologous MSCs by intrathecal route, until a total dose of 300 million. None received any other medication for its disease at the time of receiving cell therapy. Clinical and neuroimaging studies were performed previous and after the therapy, including brain glucose metabolism by 18F-FDG-PET and assessment with the visual short-term memory binding task (VSTMBT). This task has been proposed as a preclinical marker of AD. It requires subjects to detect whether or not two combinations of shape and colour change across two sequential arrays. Results: A global increase in cerebral glucose metabolism was observed after each administration of cell therapy. Single case statistics revealed that treated and untreated patients did not differ on their pre-treatment VSTMBT scores and both were significantly impaired relative to controls. The chance that an untreated AD patient would show more impairment than treated patients was 39.25% (p= 0.785) for case 1, and 50.00% (p=1.0) for case 2. This chance increased post-treatment to 97.40% (p=0.05) and 99.74% (p=0.005) respectively. Conclusion: These preliminary findings suggest that intrathecal administration of autologous MSCs should be considered as a new therapeutic strategy for Alzheimer’s dementia and deserves further studies

Reply to: Shark mortality cannot be assessed by fishery overlap alone

info:eu-repo/semantics/publishedVersio

Reply to: Caution over the use of ecological big data for conservation

info:eu-repo/semantics/publishedVersio

SPECT-TAC en la localización prequirúrgica del ganglio centinela en pacientes con cáncer de mama

Depto. de Radiología, Rehabilitación y FisioterapiaFac. de MedicinaTRUEpu